General Anesthesia Drugs Market, By Drug molecule (Desflurane, Isoflurane, Sevoflurane, Propofol, Etomidate, Methohexital, hiopentone, Midazolam, Ketamine), By Route of Administration (Intravenous Anesthesia, Inhalation Anesthesia), By End User (Hospital, Specialty Clinics, Ambulatory Surgical Centers), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Aug 2023

Code : CMI524

Pages :200

Formats :

Excel and PDF

Industry : Pharmaceutical

Leading Companies

Key players are making development of anesthesia drug and regulations of these drugs are emerging economies is also expected to boost demand of general anesthesia drug market in North America region. For instance, in May 2020, Hikma Pharmaceuticals PLC, a multinational generic drug pharmaceutical company, got quick approval from U.S. Food and Drug Administration (FDA) approval for propofol injectable emulsions during the COVID-19 outbreak, as there was surge in the demand for propofol as it was being used to as a sedative for the COVID-19 patients who were ventilated.

In April 2022, GE Healthcare, a U.S.-based multinational healthcare and medical technology company, received the U.S. Food and Drugs Approval (FDA) pre-market approval (PMA) for its End-tidal (Et) control software for general anesthesia delivery on its Aisys CS2 Anesthesia Delivery System. The device is to have a direct control of the end-tidal concentration that reflects the drug level in the patient’s blood along with that low-flow anesthesia has benefits for hospitals and the environment.

In September 2021, Medical University of Vienna had positive results from Phase IV for ADV6209 which is a new oral Midazolam formulation, on preoperative anxiety and sedation levels in paediatric anaesthesia.

In May 2021, Heron Therapeutics, Inc., a multinational biotechnology company, announced the U.S. Food and Drug Administration (FDA) approval for ZYNRELEF, which is indicated in adults for soft tissue to produce postsurgical analgesia for up to 72 hours after small-to-medium open abdominal, foot and ankle, and lower extremity total joint arthroplasty surgical procedures.